Fund Evaluator:
F/m Emerald Life Sciences Innovation ETF (LFSC)
Follow This Fund
Equity
Global Asset Class
Sector Equity
Fund Group
Health
Category
$0.000
NAV (as of )
$0.00
Minimum Initial
0.54% C
Expense Ratio
$121 Mil
Assets
Open
Status
0.00%
12b-1 Fee
0.00%
TTM Yield
0.00%
Max Load
19%
Portfolio Turnover
Best Performing in Health Over the Last Year
| 77.3% | Fidelity Advisor Biotechnology Z (FIJYX) |
| 77.1% | Fidelity Advisor Biotechnology I (FBTIX) |
| 71.4% | Eventide Healthcare & Life Sciences N (ETNHX) |
| 71.0% | Fidelity Select Biotechnology (FBIOX) |
| 58.4% | Rydex Biotechnology Inv (RYOIX) |
Data as of 6/30/2026
14.7% A
1-Mo Return
29.0% A
3-Mo Return
23.4% A
YTD Return
83.9% A
1-Yr Return
na
3-Yr Return
na
5-Yr Return
na
Category Risk Index
na
Total Risk Index
Fund Details
Fund Family
Emerald Mutual Fund Advisers Trust
Inception Date
10/30/2024
Share Class Type
Equity Investment Style
Small-Cap
Growth
Bond Investment Style
na
Socially Responsible Fund
No
Index Fund
No
Benchmark Index
N/A: 100%
Additional Fund Details
F/m Emerald Life Sciences Innovation ETF Overview
LFSC Trailing NAV Total Returns Data as of 6/30/26
| Last Month |
Last Quarter |
Ann'l. 1Yr |
Ann'l. 3Yr |
Ann'l. 5Yr |
Ann'l. 10Yr |
|
| LFSC Return (NAV) | 14.7% | 29.0% | 83.9% | na | na | na |
| LFSC Grade | A | A | A | na | na | na |
| +/- Category | 6.2% | 17.1% | 50.3% | na | na | na |
| Health Avg | 8.4% | 11.9% | 33.6% | 11.0% | 5.2% | 10.0% |
| LFSC Tax Cost Ratio | na | na | 0.0% | na | na | na |
LFSC Annual NAV Total ReturnsData as of 6/30/26
| 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
| LFSC Return (NAV) | 23.4% | 56.6% | na | na | na | na | na | na | na | na | na |
| LFSC Grade | A | A | na | na | na | na | na | na | na | na | na |
| +/- Category | 15.9% | 36.0% | na | na | na | na | na | na | na | na | na |
| Health Avg | 7.5% | 20.6% | 2.5% | 5.6% | -9.4% | 8.7% | 24.5% | 28.4% | 0.4% | 23.4% | -10.9% |
| Risk Measures | |
| Standard Deviation: | na |
| Total Risk Index: | na |
| Category Risk Index: | na |
| Category Risk Grade: | |
| Beta: | na |
| R-Squared: | na |
| Leveraged Fund: | No |
| Inverse Fund: | No |
| Portfolio Characteristics | |
| Equity Investment Style: | Small-Cap Growth |
| Bond Investment Style: | na |
| Yield: | 0.0% |
| Dividend Distribution: | Quarterly |
| Cap Gains Distribution: | Annually |
| Total Assets: | $121 Mil |
| Fund Total Assets: | $ 122 Mil |
| Share Class Type: | |
| Portfolio Turnover: | 19% |
Management Team
| Number of Managers: 5 | |||
| Longest Tenure: 1.7 years | |||
| Average Tenure: 1.7 years | |||
| Managers (Year): Garner Joseph (2024), Sears Stacey (2024), Trivedi Nishit (2024), Smith Terry M. (2024), Mertz Kenneth (2024) | |||
Portfolio Composition (as of 6/30/26)
| # of Holdings: | 40 |
| % in Top 10 Holdings: | 56.9% |
| Fund is Non-Diversified: | No |
| % in Foreign Issues: | 0.7% |
Portfolio Allocation |
|
| Domestic Stock: | 98.7% |
| Foreign Stock: | 0.7% |
| Preferred Stock: | 0.0% |
| Domestic Bond: | 0.7% |
| Foreign Bond: | 0.0% |
| Convertible Bond: | 0.0% |
| Other: | -0.0% |
| Cash: | 0.0% |
Purchase Information
| Fund Family: | Emerald Mutual Fund Advisers Trust |
| Phone Number: | 800-617-0004 |
| Website: | www.S1Fund.com. |
| Status: | Open |
| Inception Date: | October 30, 2024 |
| Min. Initial Purchase: | $ 0 |
| Min. Initial IRA Purchase: | $ 0 |
| True No-Load: | Yes |
| Front Load Maximum: | 0.00% |
| Deferred Charge Maximum: | 0.00% |
| Redemption Charge Maximum: | 0.00% |
| 12b-1 Fee: | 0.00% |
Expenses and Fees | |
| Expense Ratio (%): | 0.54% ( Rating : Avg ) |
| Category Average Expense Ratio (%): | 1.21% |
| Share Class: | F/m Emerald Life Sciences Innovation ETF |
| Min. Subsequent Purchase: | $ 0 |
| Min. Subsequent IRA Purchase: | $ 0 |
Copyright 2026 American Association of Individual Investors and Morningstar, Inc. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.